Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
49
CNVVY Quote, Financials, Valuation and Earnings
Last price:
$13.18
Seasonality move
:
-0.63%
Day range:
$13.18 - $13.53
52-week range:
$10.87 - $16.65
Dividend yield:
2.05%
P/E ratio:
30.66x
P/S ratio:
2.86x
P/B ratio:
3.49x
Volume:
46.3K
Avg. volume:
59.2K
1-year change:
19.06%
Market cap:
$6.7B
Revenue:
$2.3B
EPS (TTM):
$0.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CNVVY
Convatec Group Plc
|
-- | -- | -- | -- | -- |
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
$24.3M | -$0.40 | 84624.25% | -288.08% | $9.63 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | $8.01 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CNVVY
Convatec Group Plc
|
$13.18 | -- | $6.7B | 30.66x | $0.07 | 2.05% | 2.86x |
|
APM
Aptorum Group Ltd.
|
$1.05 | -- | $7.5M | 8.94x | $0.00 | 0% | 6.32x |
|
AUTL
Autolus Therapeutics Plc
|
$2.00 | $9.63 | $532.3M | -- | $0.00 | 0% | 10.39x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.45 | $17.94 | $2.1M | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$3.70 | $104.00 | $15.4M | -- | $0.00 | 0% | -- |
|
TLSA
Tiziana Life Sciences Ltd.
|
$1.53 | $8.01 | $181.8M | -- | $0.00 | 0% | 2,803.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CNVVY
Convatec Group Plc
|
41.04% | -0.110 | -- | 1.09x |
|
APM
Aptorum Group Ltd.
|
-- | 0.929 | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 2.916 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.608 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.467 | 0.95% | 4.03x |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -0.262 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CNVVY
Convatec Group Plc
|
-- | -- | 7.33% | 12.61% | -- | -- |
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | -- | -- |
Convatec Group Plc vs. Competitors
-
Which has Higher Returns CNVVY or APM?
Aptorum Group Ltd. has a net margin of -- compared to Convatec Group Plc's net margin of --. Convatec Group Plc's return on equity of 12.61% beat Aptorum Group Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CNVVYConvatec Group Plc-- -- $3.1B APMAptorum Group Ltd.-- -- -- -
What do Analysts Say About CNVVY or APM?
Convatec Group Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Aptorum Group Ltd. has an analysts' consensus of -- which suggests that it could grow by 14185.71%. Given that Aptorum Group Ltd. has higher upside potential than Convatec Group Plc, analysts believe Aptorum Group Ltd. is more attractive than Convatec Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings CNVVYConvatec Group Plc0 0 0 APMAptorum Group Ltd.0 0 0 -
Is CNVVY or APM More Risky?
Convatec Group Plc has a beta of 0.834, which suggesting that the stock is 16.592% less volatile than S&P 500. In comparison Aptorum Group Ltd. has a beta of -0.148, suggesting its less volatile than the S&P 500 by 114.791%.
-
Which is a Better Dividend Stock CNVVY or APM?
Convatec Group Plc has a quarterly dividend of $0.07 per share corresponding to a yield of 2.05%. Aptorum Group Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Convatec Group Plc pays 55.73% of its earnings as a dividend. Aptorum Group Ltd. pays out -- of its earnings as a dividend. Convatec Group Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CNVVY or APM?
Convatec Group Plc quarterly revenues are --, which are smaller than Aptorum Group Ltd. quarterly revenues of --. Convatec Group Plc's net income of -- is lower than Aptorum Group Ltd.'s net income of --. Notably, Convatec Group Plc's price-to-earnings ratio is 30.66x while Aptorum Group Ltd.'s PE ratio is 8.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Convatec Group Plc is 2.86x versus 6.32x for Aptorum Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNVVYConvatec Group Plc2.86x 30.66x -- -- APMAptorum Group Ltd.6.32x 8.94x -- --
-
Which has Higher Returns CNVVY or AUTL?
Autolus Therapeutics Plc has a net margin of -- compared to Convatec Group Plc's net margin of -373.3%. Convatec Group Plc's return on equity of 12.61% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital CNVVYConvatec Group Plc-- -- $3.1B AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About CNVVY or AUTL?
Convatec Group Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.63 which suggests that it could grow by 381.67%. Given that Autolus Therapeutics Plc has higher upside potential than Convatec Group Plc, analysts believe Autolus Therapeutics Plc is more attractive than Convatec Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings CNVVYConvatec Group Plc0 0 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is CNVVY or AUTL More Risky?
Convatec Group Plc has a beta of 0.834, which suggesting that the stock is 16.592% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.012, suggesting its more volatile than the S&P 500 by 101.185%.
-
Which is a Better Dividend Stock CNVVY or AUTL?
Convatec Group Plc has a quarterly dividend of $0.07 per share corresponding to a yield of 2.05%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Convatec Group Plc pays 55.73% of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend. Convatec Group Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CNVVY or AUTL?
Convatec Group Plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Convatec Group Plc's net income of -- is lower than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Convatec Group Plc's price-to-earnings ratio is 30.66x while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Convatec Group Plc is 2.86x versus 10.39x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNVVYConvatec Group Plc2.86x 30.66x -- -- AUTLAutolus Therapeutics Plc10.39x -- $21.1M -$78.6M
-
Which has Higher Returns CNVVY or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Convatec Group Plc's net margin of --. Convatec Group Plc's return on equity of 12.61% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital CNVVYConvatec Group Plc-- -- $3.1B BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About CNVVY or BDRX?
Convatec Group Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 7159.24%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Convatec Group Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Convatec Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings CNVVYConvatec Group Plc0 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is CNVVY or BDRX More Risky?
Convatec Group Plc has a beta of 0.834, which suggesting that the stock is 16.592% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.952, suggesting its less volatile than the S&P 500 by 4.8%.
-
Which is a Better Dividend Stock CNVVY or BDRX?
Convatec Group Plc has a quarterly dividend of $0.07 per share corresponding to a yield of 2.05%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Convatec Group Plc pays 55.73% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. Convatec Group Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CNVVY or BDRX?
Convatec Group Plc quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals Plc quarterly revenues of --. Convatec Group Plc's net income of -- is lower than Biodexa Pharmaceuticals Plc's net income of --. Notably, Convatec Group Plc's price-to-earnings ratio is 30.66x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Convatec Group Plc is 2.86x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNVVYConvatec Group Plc2.86x 30.66x -- -- BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns CNVVY or NCNA?
NuCana Plc has a net margin of -- compared to Convatec Group Plc's net margin of --. Convatec Group Plc's return on equity of 12.61% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital CNVVYConvatec Group Plc-- -- $3.1B NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About CNVVY or NCNA?
Convatec Group Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 562062.16%. Given that NuCana Plc has higher upside potential than Convatec Group Plc, analysts believe NuCana Plc is more attractive than Convatec Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings CNVVYConvatec Group Plc0 0 0 NCNANuCana Plc0 1 0 -
Is CNVVY or NCNA More Risky?
Convatec Group Plc has a beta of 0.834, which suggesting that the stock is 16.592% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.248%.
-
Which is a Better Dividend Stock CNVVY or NCNA?
Convatec Group Plc has a quarterly dividend of $0.07 per share corresponding to a yield of 2.05%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Convatec Group Plc pays 55.73% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend. Convatec Group Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CNVVY or NCNA?
Convatec Group Plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Convatec Group Plc's net income of -- is lower than NuCana Plc's net income of -$378.9K. Notably, Convatec Group Plc's price-to-earnings ratio is 30.66x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Convatec Group Plc is 2.86x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNVVYConvatec Group Plc2.86x 30.66x -- -- NCNANuCana Plc-- -- -- -$378.9K
-
Which has Higher Returns CNVVY or TLSA?
Tiziana Life Sciences Ltd. has a net margin of -- compared to Convatec Group Plc's net margin of --. Convatec Group Plc's return on equity of 12.61% beat Tiziana Life Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CNVVYConvatec Group Plc-- -- $3.1B TLSATiziana Life Sciences Ltd.-- -- -- -
What do Analysts Say About CNVVY or TLSA?
Convatec Group Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Tiziana Life Sciences Ltd. has an analysts' consensus of $8.01 which suggests that it could grow by 423.54%. Given that Tiziana Life Sciences Ltd. has higher upside potential than Convatec Group Plc, analysts believe Tiziana Life Sciences Ltd. is more attractive than Convatec Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings CNVVYConvatec Group Plc0 0 0 TLSATiziana Life Sciences Ltd.1 0 0 -
Is CNVVY or TLSA More Risky?
Convatec Group Plc has a beta of 0.834, which suggesting that the stock is 16.592% less volatile than S&P 500. In comparison Tiziana Life Sciences Ltd. has a beta of 0.024, suggesting its less volatile than the S&P 500 by 97.65%.
-
Which is a Better Dividend Stock CNVVY or TLSA?
Convatec Group Plc has a quarterly dividend of $0.07 per share corresponding to a yield of 2.05%. Tiziana Life Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Convatec Group Plc pays 55.73% of its earnings as a dividend. Tiziana Life Sciences Ltd. pays out -- of its earnings as a dividend. Convatec Group Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CNVVY or TLSA?
Convatec Group Plc quarterly revenues are --, which are smaller than Tiziana Life Sciences Ltd. quarterly revenues of --. Convatec Group Plc's net income of -- is lower than Tiziana Life Sciences Ltd.'s net income of --. Notably, Convatec Group Plc's price-to-earnings ratio is 30.66x while Tiziana Life Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Convatec Group Plc is 2.86x versus 2,803.69x for Tiziana Life Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNVVYConvatec Group Plc2.86x 30.66x -- -- TLSATiziana Life Sciences Ltd.2,803.69x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 16% over the past day.
Buy
71
OKLO alert for Jan 7
Oklo, Inc. [OKLO] is up 7.01% over the past day.
